Open AccessCombination Therapy With Renin‐Angiotensin‐Aldosterone Receptor Blockers for Hypertension: How Far Have We Come?
Author(s) -
Weir Matthew R.,
Bakris George L.
Publication year - 2008
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1751-7176.2008.07439.x
Subject(s) - medicine , blood pressure , thiazide , calcium channel blocker , diuretic , combination therapy , aldosterone , renin–angiotensin system , angiotensin receptor , pharmacology , angiotensin receptor blockers , diabetes mellitus , cardiology , endocrinology
In a large number of patients with hypertension, ≥2 antihypertensive agents are required to achieve blood pressure (BP) goals. There is good rationale for initial combination therapy based on clinical trials demonstrating that achievement of BP goals within a reasonably short period of time results in fewer cardiovascular events. One approach to attaining BP goals and improving medication adherence is fixed‐dose combination therapy, the use of which dates back to the 1960s. Given some of the advantages of renin‐angiotensin‐aldosterone system (RAAS) blockers in patients with heart disease, kidney disease, and diabetes, many combinations include either an angiotensin‐converting enzyme inhibitor or an angiotensin receptor blocker. In most studies, however, thiazide diuretics were necessary to achieve goal BP. Calcium channel blockers have also been used in combination with angiotensin‐converting enzyme inhibitors to lower BP. Studies are now under way to determine the relative benefits of an RAAS blocker/diuretic compared with an RAAS blocker/calcium channel blocker as initial therapy.